Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02643303 · ClinicalTrials.gov registry record · Phase 1
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
A Phase 1 study, sponsored by Ludwig Institute for Cancer Research.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
NCT02643303 is a Phase 1 study that has completed, run by Ludwig Institute for Cancer Research. The registered enrollment target is 58 participants.
The verdict
NCT02643303, a Phase 1 study, has completed, sponsored by Ludwig Institute for Cancer Research.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
Study Summary
This is an open-label, multicenter, Phase 1/2 study of the CTLA-4 antibody, tremelimumab, and the PD-L1 antibody, durvalumab (MEDI4736), in combination with the tumor microenvironment (TME) modulator poly-ICLC, a TLR3 agonist, in subjects with advanced, measurable, biopsy-accessible cancers.
Interventions
- DRUG Durvalumab
- DRUG Tremelimumab
- DRUG Poly-ICLC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2016-12-28 |
| Est. Completion | 2022-02-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02643303
The ClinicalTrials.gov registry entry for NCT02643303 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ludwig Institute for Cancer Research, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Durvalumab is the first listed.
NCT02643303 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02643303 about?
NCT02643303 is a clinical study titled "A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers". This is an open-label, multicenter, Phase 1/2 study of the CTLA-4 antibody, tremelimumab, and the PD-L1 antibody, durvalumab (MEDI4736), in combination with the tumor microenvironment (TME) modulator poly-ICLC, a TLR3 agonist, in subjects with advanced, measurable, biopsy-accessible cancers.
What is the current status of trial NCT02643303?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2016-12-28. Estimated completion is 2022-02-23.
What interventions are being tested in trial NCT02643303?
The interventions under investigation include: Durvalumab (DRUG), Tremelimumab (DRUG), Poly-ICLC (DRUG).
Who is sponsoring clinical trial NCT02643303?
This trial is sponsored by Ludwig Institute for Cancer Research, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.